Clinical Trial Update: Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of SomatoKine (Iplex), a recombinant IGF-1 and IGFBP-3 combination, in Myotonic Dystrophy Type 1 has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• SomatoKine (Iplex) rhIGF-I/rhIGFBP-3

Snippet

Sponsor: University of Rochester | Conditions: Myotonic Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-02-01